ANTIBODY-BINDING PROFILE OF PURIFIED AND CELL-BOUND CD26 - DESIGNATION OF BT5/9 AND TA5.9 TO THE CD26 CLUSTER

被引:24
作者
DEMEESTER, I
SCHARPE, S
VANHAM, G
BOSMANS, E
HEYLIGEN, H
VANHOOF, G
CORTE, G
机构
[1] INST TROP MED PRINCE LEOPOLD,PATHOL & IMMUNOL LAB,B-2000 ANTWERP,BELGIUM
[2] DR WILLEMS INST,DIEPENBEEK,BELGIUM
[3] EUROGENET,TESSENDERLO,BELGIUM
[4] UNIV GENOA,IST TUMORI,I-16126 GENOA,ITALY
关键词
D O I
10.1016/S0171-2985(11)80494-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The CD26 activation antigen (Ag) which is expressed on a subpopulation of human T cells has been characterized as dipeptidyl peptidase IV (DPP IV, EC 3.4.14.5). In this paper, we describe the antibody binding profile of CD26/DPP IV, purified from human peripheral blood lymphocytes. The purified molecule binds to the anti-Ta1, anti-1F7 and anti-134-2C2 monoclonal antibodies (mAb), reported to react with cell-bound CD26 Ag. Among unclustered mAb recognizing T cell antigens, two, anti-BT5/9 and anti-TA5.9 were found to react with purified and cell-bound CD26 Ag. The classification of the BT5/9 Ag, the functional properties of the BT5/9+ T cell subset, as well as the in vivo effect of anti-BT5/9 mAb administration, are re-interpreted in the light of its specificity. Applying the anti-TA5.9 mAb in three color FACS analyses, we demonstrated that CD26+bright cells co-express CD45RO but not HLA-DR and CD38.
引用
收藏
页码:145 / 158
页数:14
相关论文
共 53 条
[1]  
AKBAR A, 1988, J IMMUNOL, V140, P217
[2]   INTRAVENOUS MONOCLONAL-ANTIBODY (BT 5/9) FOR THE TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE [J].
BACIGALUPO, A ;
CORTE, G ;
RAMARLI, D .
ACTA HAEMATOLOGICA, 1985, 73 (03) :185-186
[3]  
BACIGALUPO A, 1987, SERONO S REV, V13, P157
[4]   BINDING OF THE T-CELL ACTIVATION MONOCLONAL-ANTIBODY TA1 TO DIPEPTIDYL PEPTIDASE-IV [J].
BARTON, RW ;
PRENDERGAST, J ;
KENNEDY, CA .
JOURNAL OF LEUKOCYTE BIOLOGY, 1990, 48 (04) :291-296
[5]   HUMAN U937-CELL SURFACE PEPTIDASE ACTIVITIES - CHARACTERIZATION AND DEGRADATIVE EFFECT ON TUMOR-NECROSIS-FACTOR-ALPHA [J].
BAUVOIS, B ;
SANCEAU, J ;
WIETZERBIN, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (04) :923-930
[6]  
BAUVOIS B, 1988, BIOCHEM J, V252, P7232
[7]   TRIGGERING OF THE PROTEINASE DIPEPTIDYL PEPTIDASE-IV (CD26) AMPLIFIES HUMAN LYMPHOCYTE-T PROLIFERATION [J].
BEDNARCZYK, JL ;
CARROLL, SM ;
MARIN, C ;
MCINTYRE, BW .
JOURNAL OF CELLULAR BIOCHEMISTRY, 1991, 46 (03) :206-218
[8]  
BLAZQUEZ MV, 1992, J IMMUNOL, V149, P3073
[9]   CIRCULATING LYMPHOCYTES-T IN HASHIMOTOS DISEASE - IMBALANCE OF SUBSETS AND PRESENCE OF ACTIVATED CELLS [J].
CANONICA, GW ;
BAGNASCO, M ;
CORTE, G ;
FERRINI, S ;
FERRINI, O ;
GIORDANO, G .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1982, 23 (03) :616-625
[10]   CIRCULATING T-CELL SUBSETS IN GRAVES-DISEASE - DIFFERENCES BETWEEN PATIENTS WITH ACTIVE DISEASE AND IN REMISSION AFTER I-131-THERAPY [J].
CANONICA, GW ;
BAGNASCO, M ;
FERRINI, S ;
BIASSONI, P ;
GIORDANO, G ;
CORTE, G .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1983, 28 (02) :265-271